Full Text
Estimation of the Additional Budget Saving Potential Due to the Rapid Adoption of An Etanercept Biosimilar (SB4) for the Treatment of Approved Adult Etanercept Indications in Spain

Abstract

Authors

E Psachoulia S Chouman

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×